In CN-AML, FLT3-ITD poor prognostic group (n=19) revealed inferior clinical outcome (median OS 7.2 months, P<0.001; median EFS 5.3 months, P<0.001) as like in entire patients. Here, FLT3 is linked to acute myeloid leukemia.